Novo Nordisk, the renowned manufacturer of weight-loss and diabetes medications such as Ozempic and Wegovy, is making headlines with its ambitious new leader, Maziar Mike Doustdar. The company’s recent aggressive move—a bid of $9 billion for Metsera—signals a significant shift in its approach to acquisitions, showcasing its resolve to expand its influence in the competitive market for obesity medications.
The bid is particularly striking as it disrupts the current agreement between Metsera and Pfizer, which is valued at up to $7.3 billion. Novo’s proposed offer includes a premium of 133 percent over Metsera’s trading price just prior to the announcement of the Pfizer deal, reflecting the urgency and ambition behind this move.
Novo Nordisk’s proposal also comes with unique structuring aimed at mitigating concerns among Metsera’s shareholders, particularly regarding potential antitrust barriers. The company plans to offer $6.5 billion in cash while securing a 50 percent stake in a class of shares that do not carry voting rights. This cash would be distributed to Metsera’s current investors as a dividend ahead of any antitrust discussions. Should the acquisition move forward successfully with regulatory approval, Novo is prepared to pay up to an additional $2.5 billion, contingent on specific milestones.
However, this strategy carries inherent risks. If regulatory bodies block the acquisition, Novo could find itself holding a sizable, non-voting minority stake in Metsera. Despite this uncertainty, industry analysts believe the risk is manageable, especially considering the robust appetite in the obesity medication market. Should the acquisition fail, Novo could potentially attract other buyers, including Pfizer or different pharmaceutical entities seeking to expand their portfolios.
As the competition heats up, Pfizer now has just four days to consider raising its own offer for Metsera, knowing it must respond to Novo’s assertive bid. The situation presents challenges for Pfizer, especially as it has not yet established a foothold in the lucrative obesity drug sector, unlike its rivals.
Novo Nordisk’s aggressive strategy is a direct response to its recent setbacks, including a notable decline in its market value and the loss of key personnel, including its chief executive. With the impending expiration of its semaglutide patent, the urgency to diversify and bolster its offerings is more apparent than ever.
In just a month, Novo Nordisk has committed to potential deals worth a staggering $16.3 billion, including this latest bid for Metsera. Furthermore, analysts suggest that by increasing its net debt to twice its EBITDA, Novo could free up an additional $20 billion for further acquisitions.
This relentless pursuit of growth is expected to have positive implications for biotechnology firms focused on obesity treatments. For instance, shares of metabolic medicine biotech Viking Therapeutics surged over 11 percent following the news, and oral obesity drug developer Structure Therapeutics saw a rise of more than 5 percent.
As the landscape of obesity treatments continues to evolve, Novo Nordisk’s bold maneuvers demonstrate its ambition to reclaim its leading position in a highly competitive sector, leaving both investors and industry watchers keenly interested in the outcome of this acquisition battle.
